The Eli Lilly, Pfizer and Sanofi-backed cancer therapy developer raised $150m despite reducing the number of shares in the IPO and floating beneath its range.

The underwriters for Karolinska Institute spinout Aprea Therapeutics have taken up the over-allotment option in full to boost proceeds to nearly $97.8m.

The underwriters for Praktikertjänst-backed Aprea Therapeutics have taken up the over-allotment option in full to boost proceeds to nearly $97.8m.

The AstraZeneca-backed cancer drug developer had hoped to raise up to $212m in a US flotation but is instead pulling back due to unfavourable market conditions.

Emtek is set to sell up to $55m of its shares in online real estate platform PropertyGuru in an Australian initial public offering that could bring in up to $257m in proceeds.

AstraZeneca spinoff Viela Bio has gone public in an offering that involved existing backers buying some $70m worth of stock, and its share price has since risen 21.7%.

Karolinska Institute's Aprea Therapeutics has priced its shares at $15 to raise $85m, with stock rising a third to $20.50 on the first day of trading.

Praktikertjänst-backed Aprea Therapeutics has priced its shares at $15 to raise $85m, with stock rising a third to $20.50 on the first day of trading.

Frequency, a regenerative medicine developer based on MIT and Harvard research, priced shares at the bottom of its range to raise $84m in its IPO.

The Alexandria Real Estate Equities-backed regenerative medicine developer floated at the bottom of its range while cutting the number of shares.